UPR 5301

Creation of the new start-up resulting from the work of Cermav, AIS Biotech

26 May 2023

AIS Biotech relies on innovative, efficient, industrializable biotechnology with low environmental impact, to develop a new class of anti-infective biomedicines. Click on the title for more information.

The technology licensed to AIS Biotech is based on the historical work of Cermav, which was matured in collaboration with the CIRI laboratory in Lyon thanks to funding from SATT Linksium.

It is highlighted in CNRS Innovation Letter.